公开(公告)号：US12109195B2

公开(公告)日：2024-10-08

申请号：US17363193

申请日：2021-06-30

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Deeannah Seymour

IPC分类号： A61K31/41 ,  A61K9/00 ,  A61K9/02 ,  A61K31/194 ,  A61K31/4168 ,  A61K31/7016 ,  A61K31/702 ,  A61K31/733 ,  A61K33/22 ,  A61K35/747 ,  A61P31/04

CPC分类号： A61K31/4168 ,  A61K9/0036 ,  A61K9/02 ,  A61K31/194 ,  A61K31/7016 ,  A61K31/702 ,  A61K31/733 ,  A61K33/22 ,  A61K35/747 ,  A61P31/04

摘要： Compositions and methods for treatment and prevention of vaginal infections where the compositions include creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD.

公开(公告)号：US20240307431A1

公开(公告)日：2024-09-19

申请号：US18274568

申请日：2022-01-28

申请人： Centre National de la Recherche Scientifique (CNRS) ,  Ecole Normale Superieure de Lyon ,  INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université Claude Bernard Lyon 1

发明人： Eric SAMAIN ,  Manuel ROSA-CALATRAVA ,  Aurélien TRAVERSIER ,  Emeline RICHARD

IPC分类号： A61K31/715 ,  A61K31/702 ,  A61P31/16 ,  C07H15/12 ,  C08B37/00

CPC分类号： A61K31/715 ,  A61K31/702 ,  A61P31/16 ,  C07H15/12 ,  C08B37/006

摘要： The invention relates to a synthetic sialoside presenting the formula (I): Neu5-Ac-α2-6-R1(R2)[GlcNAcβ1-4]n-GlcNAc Formula wherein: -GlcNAc is N-acetylglucosamine; -GlcNAcβ1-4 ia a N-acetylglucosamine unit linked with a β1-4 link; -n is a superior or equal to 1; -R1 is a glycan structure comprising at least one galactose (Gal); and -R2 is chosen among the following groups: H, fucose linked with a α1-3 link (Fucα1-3) or a1-4 link (Fucα1-4).

公开(公告)号：US20240293485A1

公开(公告)日：2024-09-05

申请号：US18572429

申请日：2022-06-21

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： SAMI DAMAK ,  MARC GARCIA-GARCERA ,  BERNARD BERGER ,  FABIO MAINARDI ,  CLARA LUCIA GARCIA-RODENAS ,  SHAILLAY KUMAR DOGRA

IPC分类号： A61K35/747 ,  A61K31/702 ,  A61K31/717 ,  A61K31/732 ,  A61K31/736 ,  A61K35/00 ,  A61K35/745 ,  A61K36/42 ,  A61K36/55 ,  A61K36/736 ,  A61P1/14

CPC分类号： A61K35/747 ,  A61K31/702 ,  A61K31/717 ,  A61K31/732 ,  A61K31/736 ,  A61K35/745 ,  A61K36/42 ,  A61K36/55 ,  A61K36/736 ,  A61P1/14 ,  A61K2035/115

摘要： A composition contains a combination of at least one fiber and at least one probiotic and is formulated for administration to a subject such that the combination of at least one fiber and at least one probiotic enhance resilience of the microbiome in the subject. Preferably the subject is experiencing a microbiome stressor, will experience a microbiome stressor and/or has recently experienced a microbiome stressor, such as one or more of a dietary stressor, antibiotic, other medications, infections, intense exercise, stress, alcohol, travel and combinations thereof; more preferably at least a dietary stressor; most preferably at least a high fat diet, such as a Western high fat diet or a ketogenic diet. The method can achieve at least one result that is (i) prevention or attenuation of perturbation of microbiota; (ii) recovery after perturbation; and (iii) normalization of one or more of stool frequency, intestinal transit, constipation, gut permeability, endotoxemia or gut barrier function.

公开(公告)号：US20240293437A1

公开(公告)日：2024-09-05

申请号：US18420540

申请日：2024-01-23

申请人： DSM IP Assets B.V.

发明人： Stephane DUVAL ,  John Michael GEREMIA ,  Lisa Ann LAPRADE ,  April WAGUESPACK-LEVY ,  Estefania PEREZ CALVO ,  Ghislain SCHYNS ,  Viviane VERLHAC ,  Joshua Thomas CLAYPOOL

IPC分类号： A61K31/702 ,  A23K20/163 ,  A23K50/30 ,  A23K50/75

CPC分类号： A61K31/702 ,  A23K20/163 ,  A23K50/30 ,  A23K50/75

摘要： Methods of feeding animals are disclosed wherein providing feed additives are provided that modulate the gut microbiome to improve the health, nutrition, and growth performance. Methods of modulating the microbial species present in the gastrointestinal tract of an animal are also disclosed. Such modulation includes, for example, modulating the level or function of microbial species.

公开(公告)号：US20240261310A1

公开(公告)日：2024-08-08

申请号：US18560456

申请日：2021-05-14

申请人： HAITANG (JIANGSU) BIOTECHNOLOGY COMPANY, LTD.

发明人： Zhende Liu ,  Heyong Gao

IPC分类号： A61K31/702 ,  A61K31/7016 ,  A61P13/12

CPC分类号： A61K31/702 ,  A61K31/7016 ,  A61P13/12

摘要： The present invention provides an alginate oligosaccharide or a pharmaceutically acceptable salt thereof in preparation of a drug for treatment of acute kidney injury, wherein the alginate oligosaccharide is an alginate disaccharide, an alginate trisaccharide, or an alginate tetrasaccharide. Studies have found that the alginate disaccharide, the alginate trisaccharide, and the alginate tetrasaccharide all show significant protective effects on animal models of acute kidney injury induced by ischemia-reperfusion (I/R), endotoxin phosphorus lipopolysaccharides (LPS) and anti-tumor drug cisplatin. After the treatment of acute kidney injury animals by the alginate oligosaccharide of the present invention, the level of serum creatinine decreases significantly, the urine concentration ability of kidneys recovers significantly, the level of renal tubular injury markers (KIM-1 and NGAL) is significantly reduced, the protein expression of inflammatory factors is significantly reduced, the pathological changes of the kidneys are significantly ameliorated, and the therapeutic effect is enhanced with the increase of dose. Therefore, the alginate oligosaccharide of the present invention has a strong effect in the treatment of acute kidney injury.

公开(公告)号：US20240207347A1

公开(公告)日：2024-06-27

申请号：US18528808

申请日：2023-12-05

申请人： TCI CO., LTD.

发明人： YUNG-HSIANG LIN ,  FAN-JHEN DAI ,  YIN-DI SU

IPC分类号： A61K36/736 ,  A61K8/9789 ,  A61K31/702 ,  A61P7/06 ,  A61P17/10 ,  A61Q17/04

CPC分类号： A61K36/736 ,  A61K8/9789 ,  A61K31/702 ,  A61P7/06 ,  A61P17/10 ,  A61Q17/04

摘要： A method for inhibiting skin damage caused by blue light, reducing skin sagging, reducing skin porphyrin content, or increasing ferritin content in a subject in need thereof is provided. The method includes: administering to the subject an effective dose of queen plum extract. The queen plum extract is obtained by extracting whole fruit of Prunussalicina by water. The queen plum extract has at least one of the following effects: inhibiting skin damage caused by blue light, improving skin sagging, reducing skin porphyrin content or increasing ferritin content.

公开(公告)号：US12016869B2

公开(公告)日：2024-06-25

申请号：US16897117

申请日：2020-06-09

申请人： FONTERRA CO-OPERATIVE GROUP LIMITED

发明人： Alan David Welman ,  Geoffrey Stevens ,  Christopher Paul McJarrow ,  Bertram Yin Fong ,  Bing Wang

IPC分类号： A61K31/702 ,  A23C9/12 ,  A23C9/142 ,  A23L33/00 ,  A23L33/135 ,  A61K35/745 ,  A61K35/747 ,  A61P25/00 ,  A61P25/28 ,  C12N9/04 ,  C12N9/38

CPC分类号： A61K31/702 ,  A23C9/12 ,  A23C9/1206 ,  A23C9/142 ,  A23C9/1422 ,  A23C9/1427 ,  A23L33/135 ,  A23L33/40 ,  A61K35/745 ,  A61K35/747 ,  A61P25/00 ,  A61P25/28 ,  C12N9/0006 ,  C12N9/2471 ,  A23C2210/20 ,  A23C2210/206 ,  A23V2002/00 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/284

摘要： A method of producing sialyloligosaccharides a sialyloligosaccharides-containing source that also contains carbohydrates and minerals. The process includes subjecting the source to a temperature of from about 67° C. and (i) filtration with a heat-resistant filter at a temperature of about 35 to about 95° C. to produce a first retentate and first permeate, or (ii) centrifugal separation to produce a light phase and a heavy phase and filtration of the light phase at a temperature of about 50 to about 70° C. to produce a first retentate and first permeate, (b) nanofiltration of the first permeate, or nanofiltration and diafiltration of the first permeate, to produce a second retentate and second permeate, and (c) concentration of the second retentate, to produce a sialyloligosaccharide-containing extract. Additionally, the invention relates to a sialyloligosaccharide-enriched composition comprising at least 3′-sialyllactose and 6′-sialyllactose and its use in, for example, nutritional and infant formulas, and for maintaining or improving cognitive function.

公开(公告)号：US12016334B2

公开(公告)日：2024-06-25

申请号：US16955326

申请日：2019-11-08

申请人： SEA6ENERGY PVT. LTD.

发明人： Girish Tavarekere Rudrappa ,  Hemanth Giri Rao Vantharam Venkata ,  Pooja Malhotra ,  Sumit Purushottam Bhose ,  Narendrakumar Sekar ,  Sam Kuruvilla ,  Lekshmi Girija ,  Sachin Khandelwal ,  Nithin Sanghe ,  Sawan Kumar ,  Sri Sailaja Nori ,  Shrikumar Suryanarayan

IPC分类号： A01N41/02 ,  A01N43/16 ,  A61K9/00 ,  A61K31/195 ,  A61K31/60 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/702 ,  A61K33/22 ,  A61K33/30 ,  A61K36/04 ,  A61P31/00

CPC分类号： A01N41/02 ,  A01N43/16 ,  A61K9/0056 ,  A61K31/195 ,  A61K31/60 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/702 ,  A61K33/22 ,  A61K33/30 ,  A61K36/04 ,  A61P31/00

摘要： The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.

公开(公告)号：US20240173341A1

公开(公告)日：2024-05-30

申请号：US18508838

申请日：2023-11-14

申请人： Advanced Protein Technologies Corp.

发明人： Chul Soo SHIN ,  Jong Won YOON ,  Seon Min JEON ,  Young Ha SONG ,  Jong Gil YOO ,  Jeong Su BANG

IPC分类号： A61K31/702 ,  A61P25/28

CPC分类号： A61K31/702 ,  A61P25/28

摘要： Disclosed is a method for, preventing, ameliorating or treating dementia by administering a composition containing 2′-fucosyllactose. 2′-FL ameliorates brain damage caused by amyloid beta and neuroinflammation by suppressing or preventing accumulation of the amyloid beta, thus being highly effective in preventing, ameliorating and treating dementia.

公开(公告)号：US11986487B2

公开(公告)日：2024-05-21

申请号：US17934123

申请日：2022-09-21

申请人： GLYCOM A/S

发明人： Louise Kristine Vigsnæs ,  Bruce McConnell

IPC分类号： A61K31/702 ,  A23L33/00 ,  A23L33/21 ,  A61P1/00

CPC分类号： A61K31/702 ,  A23L33/21 ,  A23L33/40 ,  A61P1/00

摘要： The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.